ATE257379T1 - Verwendung von aryl- (oder heteroaryl-) azoylcarbinolderivaten zur behandlung von durch überschuss von substanz p hervorgerufenen beschwerden - Google Patents

Verwendung von aryl- (oder heteroaryl-) azoylcarbinolderivaten zur behandlung von durch überschuss von substanz p hervorgerufenen beschwerden

Info

Publication number
ATE257379T1
ATE257379T1 AT99940199T AT99940199T ATE257379T1 AT E257379 T1 ATE257379 T1 AT E257379T1 AT 99940199 T AT99940199 T AT 99940199T AT 99940199 T AT99940199 T AT 99940199T AT E257379 T1 ATE257379 T1 AT E257379T1
Authority
AT
Austria
Prior art keywords
azoylcarbinol
heteroaryl
aryl
excess
derivatives
Prior art date
Application number
AT99940199T
Other languages
German (de)
English (en)
Inventor
Ramon Merce-Vidal
Jordi Frigola-Constansa
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Application granted granted Critical
Publication of ATE257379T1 publication Critical patent/ATE257379T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT99940199T 1998-08-07 1999-08-05 Verwendung von aryl- (oder heteroaryl-) azoylcarbinolderivaten zur behandlung von durch überschuss von substanz p hervorgerufenen beschwerden ATE257379T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES009801708A ES2150378B1 (es) 1998-08-07 1998-08-07 Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p.
PCT/ES1999/000255 WO2000007542A2 (es) 1998-08-07 1999-08-05 Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p

Publications (1)

Publication Number Publication Date
ATE257379T1 true ATE257379T1 (de) 2004-01-15

Family

ID=8304839

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99940199T ATE257379T1 (de) 1998-08-07 1999-08-05 Verwendung von aryl- (oder heteroaryl-) azoylcarbinolderivaten zur behandlung von durch überschuss von substanz p hervorgerufenen beschwerden

Country Status (26)

Country Link
US (1) US6518295B1 (https=)
EP (1) EP1103243B1 (https=)
JP (1) JP2002522359A (https=)
KR (1) KR100558506B1 (https=)
CN (1) CN1151789C (https=)
AR (1) AR019999A1 (https=)
AT (1) ATE257379T1 (https=)
AU (1) AU754124B2 (https=)
BR (1) BR9912807A (https=)
CA (1) CA2339661C (https=)
CO (1) CO5080747A1 (https=)
CZ (1) CZ292065B6 (https=)
DE (1) DE69914085T8 (https=)
DK (1) DK1103243T3 (https=)
ES (2) ES2150378B1 (https=)
HU (1) HUP0105428A3 (https=)
IL (1) IL141295A0 (https=)
NO (1) NO20010634L (https=)
NZ (1) NZ509645A (https=)
PL (1) PL193802B1 (https=)
PT (1) PT1103243E (https=)
RU (1) RU2223116C2 (https=)
TR (1) TR200100378T2 (https=)
TW (1) TW445259B (https=)
WO (1) WO2000007542A2 (https=)
ZA (1) ZA200100867B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2174756B2 (es) * 2001-04-06 2003-11-16 Esteve Labor Dr Derivados de aril (o heteroaril) azolilcarbinoles para el tratamiento de enfermedades respiratorias.
US20040142929A1 (en) * 2001-07-06 2004-07-22 Ramon Merce-Vidal Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence
ES2180449B1 (es) * 2001-07-06 2004-01-16 Esteve Labor Dr Derivados de aril (o heteroaril) azolilcarbinoles para el tratamiento de la incontinencia urinaria.
DE10335566A1 (de) * 2003-07-31 2005-02-24 Grünenthal GmbH Arzneimittel enthaltend Derivate von Aryl( oder Heteroaryl)azolylcarbinolen
EP1584335A3 (en) * 2004-04-05 2006-02-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising a carbinol composition and an opioid
ES2244326B1 (es) * 2004-04-05 2007-02-16 Laboratorios Del Dr. Esteve, S.A. Combinacion de substancias activas.
EP1784178A1 (en) * 2004-07-30 2007-05-16 Laboratorios Del Dr. Esteve, S.A. Aryl (or heteroaryl) azolylcarbinols
CA2580694A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
EP1690537A1 (en) * 2005-02-15 2006-08-16 Laboratorios Del Dr. Esteve, S.A. Derivatives of aryl(or heteroaryl) azolycarbinols for the treatment of fibromyalgia
ES2286920B1 (es) * 2005-02-15 2008-08-16 Laboratorios Del Dr. Esteve, S.A. Derivados de aril (o heteroaril)azolilcarbinoles para el tratamiento de la fibromialgia.
EP1695704A1 (en) * 2005-02-28 2006-08-30 Laboratorios Del Dr. Esteve, S.A. Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia
WO2006087147A2 (en) * 2005-02-15 2006-08-24 Laboratorios Del Dr. Esteve, S.A. Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia
AU2007209381A1 (en) * 2006-01-27 2007-08-02 F. Hoffmann-La Roche Ag Use of substituted 2-imidazole of imidazoline derivatives
EP1820502A1 (en) * 2006-02-10 2007-08-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising azolylcarbinol compounds
AU2007312390B2 (en) 2006-10-19 2013-03-28 F. Hoffmann-La Roche Ag Aminomethyl-4-imidazoles
CA2668454A1 (en) 2006-11-02 2008-05-08 F. Hoffmann-La Roche Ag Substituted 2-imidazoles
WO2008058867A2 (en) 2006-11-16 2008-05-22 F. Hoffmann-La Roche Ag Substituted 4-imidazoles
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
ES2364701T3 (es) 2006-12-13 2011-09-12 F. Hoffmann-La Roche Ag Nuevos 2-imidazoles como ligandos para receptores asociados a aminas trazas.
EP2114906B1 (en) 2007-02-02 2014-08-06 F. Hoffmann-La Roche AG 2-aminooxazolines as taar1 ligands for cns disorders
CA2676944C (en) 2007-02-15 2016-01-19 F. Hoffmann-La Roche Ag 2-aminooxazolines as taar1 ligands
WO2009003868A2 (en) 2007-07-02 2009-01-08 F. Hoffmann-La Roche Ag 2 -imidazolines having a good affinity to the trace amine associated receptors (taars)
AU2008270444A1 (en) 2007-07-03 2009-01-08 F. Hoffmann-La Roche Ag 4-imidazolines and their use as antidepressants
CA2694362A1 (en) 2007-07-27 2009-02-05 F. Hoffmann-La Roche Ag 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as taar-ligands
AU2008285795A1 (en) 2007-08-03 2009-02-12 F. Hoffmann-La Roche Ag Pyridinecarboxamide and benzamide derivatives as TAAR1 ligands
US8242153B2 (en) 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
WO2010123999A2 (en) * 2009-04-21 2010-10-28 Auspex Pharmaceuticals, Inc. 1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
WO2017157873A1 (en) 2016-03-17 2017-09-21 F. Hoffmann-La Roche Ag 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2613720B1 (fr) * 1987-04-10 1990-01-19 Esteve Labor Dr Derives d'aryl-heteroaryl carbinols avec activite analgesique
FR2681322B1 (fr) * 1991-09-12 1993-12-17 Laboratorios Dr Esteve Sa Derives d'aryl-heteroaryl-{n-[2-(3,4-dimethoxyphenyl)-ethyl]-n-methyl-3-aminopropoxy}-methane leur preparation et leur application en tant que medicaments .
CA2154116A1 (en) * 1994-07-22 1996-01-23 Philip Arthur Hipskind 1-aryl-2-acetamidopentanone derivatives for use as tachykinin receptor antagonists
FR2742147B1 (fr) * 1995-12-06 1998-02-27 Esteve Labor Dr Procede de separation de carbinols
CA2273807A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating schizophrenic disorders
CA2273853A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating cognitive disorders
EP0942734A1 (en) * 1996-12-02 1999-09-22 MERCK SHARP & DOHME LTD. Use of nk-1 receptor antagonists for treating severe anxiety disorders
DE69732133T2 (de) * 1996-12-02 2005-12-22 Merck Sharp & Dohme Ltd., Hoddesdon Verwendung von NK-1 Rezeptorantagonisten zur Behandlung von schweren Depressionen
ES2150353B1 (es) * 1998-04-15 2001-07-01 Esteve Labor Dr Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos.

Also Published As

Publication number Publication date
ES2150378B1 (es) 2001-07-01
CO5080747A1 (es) 2001-09-25
EP1103243B1 (en) 2004-01-07
CZ2001412A3 (cs) 2001-08-15
KR100558506B1 (ko) 2006-03-07
KR20010079616A (ko) 2001-08-22
CA2339661A1 (en) 2000-02-17
CN1151789C (zh) 2004-06-02
JP2002522359A (ja) 2002-07-23
ES2150378A1 (es) 2000-11-16
HUP0105428A3 (en) 2003-01-28
DK1103243T3 (da) 2004-05-03
BR9912807A (pt) 2001-10-16
AU5422999A (en) 2000-02-28
WO2000007542A2 (es) 2000-02-17
NO20010634L (no) 2001-04-06
AU754124B2 (en) 2002-11-07
PL346221A1 (en) 2002-01-28
US6518295B1 (en) 2003-02-11
WO2000007542A3 (es) 2000-05-11
TW445259B (en) 2001-07-11
NO20010634D0 (no) 2001-02-06
ZA200100867B (en) 2001-08-16
PL193802B1 (pl) 2007-03-30
CN1317966A (zh) 2001-10-17
DE69914085T8 (de) 2005-04-21
AR019999A1 (es) 2002-03-27
CA2339661C (en) 2006-10-17
IL141295A0 (en) 2002-12-01
RU2223116C2 (ru) 2004-02-10
CZ292065B6 (cs) 2003-07-16
EP1103243A2 (en) 2001-05-30
DE69914085D1 (de) 2004-02-12
NZ509645A (en) 2003-01-31
ES2213380T3 (es) 2004-08-16
TR200100378T2 (tr) 2001-06-21
DE69914085T2 (de) 2004-11-25
HUP0105428A2 (hu) 2002-05-29
PT1103243E (pt) 2004-05-31

Similar Documents

Publication Publication Date Title
ATE257379T1 (de) Verwendung von aryl- (oder heteroaryl-) azoylcarbinolderivaten zur behandlung von durch überschuss von substanz p hervorgerufenen beschwerden
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE50009504D1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
DE69936890D1 (de) Vorrichtung zur Behandlung von Ischämie
DE60105295D1 (de) Chinazolinderivate zur behandlung von tumoren
DE60025369D1 (de) Unterchlorige säure enthaltendes superoxidiertes wasser zur behandlung von wunden
ATE235481T1 (de) Substituierte benzopyranderivate zur behandlung von entzündungen
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE60211913D1 (de) Aryl- (oder heteroaryl-) azolylcarbynolderivatve zur behandlung von harninkontinenz
DE69943089D1 (de) Methode zur behandlung von staphylokokkeninfektionen
DE69835419D1 (de) Verfahren zur Behandlung von organischem Abwasser
DE60030861D1 (de) Verwendung von escitalopram zur Behandlung von generalisierten Angstzuständen
DE69939723D1 (de) Verwendung von Intereferon Gamma zur Behandlung von Herzhypertrophie
DE69834578D1 (de) Verfahren zur behandlung von zementaufschlämmungen
DE60018200D1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
DE69913380D1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen
DE60021252D1 (de) Antikonvulsiva zur behandlung von autismus
ATE433323T1 (de) Verwendung von erythropoietin zur behandlung von primärer hämochromatosen
DE60120990D1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
DE69906969D1 (de) Verwendung von aryl(oder heteroaryl)-azolylcarbinolderivaten in der herstellung von medikamenten zur behandlung von neurogenen entzündungen
DE60023555D1 (de) Verfahren zur behandlung von gewebe
DE60200713D1 (de) Zusammensetzung enthaltend getrocknetes Vollei zur Behandlung von Hepatitis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1103243

Country of ref document: EP

REN Ceased due to non-payment of the annual fee